Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT

Founder-led company

Arcturus Therapeutics Holdings stock price today

$17.44
+0.42
+2.47%
Financial Health
0
1
2
3
4
5
6
7
8
9

Arcturus Therapeutics Holdings stock price monthly change

-26.51%
month

Arcturus Therapeutics Holdings stock price quarterly change

-26.51%
quarter

Arcturus Therapeutics Holdings stock price yearly change

-48.03%
year

Arcturus Therapeutics Holdings key metrics

Market Cap
417.14M
Enterprise value
412.20M
P/E
77.06
EV/Sales
1.72
EV/EBITDA
-7.03
Price/Sales
2.99
Price/Book
2.63
PEG ratio
0.73
EPS
-3.91
Revenue
113.75M
EBITDA
-106.49M
Income
-104.16M
Revenue Q/Q
-59.11%
Revenue Y/Y
-59.40%
Profit margin
-26.59%
Oper. margin
-25.3%
Gross margin
5.61%
EBIT margin
-25.3%
EBITDA margin
-93.62%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Arcturus Therapeutics Holdings stock price history

Arcturus Therapeutics Holdings stock forecast

Arcturus Therapeutics Holdings financial statements

Average Price Target
Last Year

$73

Potential upside: 318.57%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Profit margin
Jun 2023 9.56M -52.55M -549.4%
Sep 2023 43.37M -16.22M -37.4%
Dec 2023 28.21M -8.57M -30.39%
Mar 2024 32.59M -26.81M -82.27%
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Debt to assets
Jun 2023 430646000 145.47M 33.78%
Sep 2023 457650000 177.58M 38.8%
Dec 2023 429402000 150.88M 35.14%
Mar 2024 418849000 154.87M 36.98%
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Cash Flow
Jun 2023 50.80M -354K 94K
Sep 2023 -32.40M -981K 21.84M
Dec 2023 -544.67K -837.07K -17.98M
Mar 2024 -5.55M -240K 2.18M

Arcturus Therapeutics Holdings alternative data

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Employee count
Aug 2023 170
Sep 2023 170
Oct 2023 170
Nov 2023 170
Dec 2023 170
Jan 2024 170
Feb 2024 170
Mar 2024 180
Apr 2024 180
May 2024 180
Jun 2024 180
Jul 2024 180

Arcturus Therapeutics Holdings other data

61.51% -24.62%
of ARCT is owned by hedge funds
16.66M -6.13M
shares is hold by hedge funds

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 26000
Jun 2024 0 76114
Oct 2024 0 12000
Transaction Date Insider Security Shares Price per share Total value Source
Sale
CHIVUKULA PAD officer: Chief Scientific Offic..
Common Stock 12,000 $20.76 $249,120
Option
MARANTZ JING L. director
Common Stock 3,131 N/A N/A
Option
MARANTZ JING L. director
Deferred Stock Units 3,131 N/A N/A
Option
HOLMES EDWARD W director
Common Stock 3,131 N/A N/A
Option
HOLMES EDWARD W director
Deferred Stock Units 3,131 N/A N/A
Option
MARKELS JOHN director
Common Stock 3,131 N/A N/A
Option
MARKELS JOHN director
Deferred Stock Units 3,131 N/A N/A
Option
MARQUET MAGDA director
Common Stock 3,131 N/A N/A
Option
MARQUET MAGDA director
Deferred Stock Units 3,131 N/A N/A
Option
BARLOW JAMES F director
Common Stock 3,131 N/A N/A
Insider Compensation
Mr. Joseph E. Payne M.Sc. (1972) Founder, Pres, Chief Executive Officer & Director
$950,000
Dr. Steven George Hughes M.B.A., M.D. (1967) Chief Medical Officer
$664,000
Dr. Padmanabh Chivukula (1979) Founder, Chief Scientific Officer, Chief Operating Officer & Sec.
$640,000
Mr. Andrew H. Sassine (1964) Chief Financial Officer & Director
$640,000
Monday, 16 December 2024
businesswire.com
Tuesday, 26 November 2024
businesswire.com
Monday, 18 November 2024
businesswire.com
Thursday, 14 November 2024
seekingalpha.com
businesswire.com
Monday, 11 November 2024
businesswire.com
Thursday, 7 November 2024
seekingalpha.com
zacks.com
Monday, 4 November 2024
zacks.com
Wednesday, 30 October 2024
zacks.com
Tuesday, 1 October 2024
zacks.com
Monday, 30 September 2024
prnewswire.com
Monday, 16 September 2024
zacks.com
Friday, 13 September 2024
zacks.com
prnewswire.com
Monday, 2 September 2024
zacks.com
Friday, 23 August 2024
zacks.com
zacks.com
Friday, 9 August 2024
seekingalpha.com
Monday, 5 August 2024
seekingalpha.com
zacks.com
businesswire.com
Thursday, 18 July 2024
businesswire.com
Thursday, 20 June 2024
businesswire.com
Saturday, 8 June 2024
seekingalpha.com
Friday, 7 June 2024
businesswire.com
Tuesday, 28 May 2024
businesswire.com
Monday, 20 May 2024
prnewswire.com
businesswire.com
Wednesday, 15 May 2024
businesswire.com
  • What's the price of Arcturus Therapeutics Holdings stock today?

    One share of Arcturus Therapeutics Holdings stock can currently be purchased for approximately $17.44.

  • When is Arcturus Therapeutics Holdings's next earnings date?

    Unfortunately, Arcturus Therapeutics Holdings's (ARCT) next earnings date is currently unknown.

  • Does Arcturus Therapeutics Holdings pay dividends?

    No, Arcturus Therapeutics Holdings does not pay dividends.

  • How much money does Arcturus Therapeutics Holdings make?

    Arcturus Therapeutics Holdings has a market capitalization of 417.14M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 23.33% to 157.75M US dollars.

  • What is Arcturus Therapeutics Holdings's stock symbol?

    Arcturus Therapeutics Holdings Inc. is traded on the NASDAQ under the ticker symbol "ARCT".

  • What is Arcturus Therapeutics Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Arcturus Therapeutics Holdings?

    Shares of Arcturus Therapeutics Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Arcturus Therapeutics Holdings's key executives?

    Arcturus Therapeutics Holdings's management team includes the following people:

    • Mr. Joseph E. Payne M.Sc. Founder, Pres, Chief Executive Officer & Director(age: 53, pay: $950,000)
    • Dr. Steven George Hughes M.B.A., M.D. Chief Medical Officer(age: 58, pay: $664,000)
    • Dr. Padmanabh Chivukula Founder, Chief Scientific Officer, Chief Operating Officer & Sec.(age: 46, pay: $640,000)
    • Mr. Andrew H. Sassine Chief Financial Officer & Director(age: 61, pay: $640,000)
  • Is Arcturus Therapeutics Holdings founder-led company?

    Yes, Arcturus Therapeutics Holdings is a company led by its founders Mr. Joseph E. Payne M.Sc. and Dr. Padmanabh Chivukula.

  • How many employees does Arcturus Therapeutics Holdings have?

    As Jul 2024, Arcturus Therapeutics Holdings employs 180 workers.

  • When Arcturus Therapeutics Holdings went public?

    Arcturus Therapeutics Holdings Inc. is publicly traded company for more then 12 years since IPO on 22 May 2013.

  • What is Arcturus Therapeutics Holdings's official website?

    The official website for Arcturus Therapeutics Holdings is arcturusrx.com.

  • Where are Arcturus Therapeutics Holdings's headquarters?

    Arcturus Therapeutics Holdings is headquartered at 10628 Science Center Drive, San Diego, CA.

  • How can i contact Arcturus Therapeutics Holdings?

    Arcturus Therapeutics Holdings's mailing address is 10628 Science Center Drive, San Diego, CA and company can be reached via phone at 858 900 2660.

  • What is Arcturus Therapeutics Holdings stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Arcturus Therapeutics Holdings in the last 12 months, the avarage price target is $73. The average price target represents a 318.57% change from the last price of $17.44.

Arcturus Therapeutics Holdings company profile:

Arcturus Therapeutics Holdings Inc.

arcturusrx.com
Exchange:

NASDAQ

Full time employees:

180

Industry:

Biotechnology

Sector:

Healthcare

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

10628 Science Center Drive
San Diego, CA 92121

CIK: 0001768224
ISIN: US03969T1097
CUSIP: 03969T109